I am dating an Oncologist who turned me on to PCYC over a year ago. He said people just don't understand the implications of the data. Definitely more BITE than bling! Implications suggest a faster track to approval and ibrutinib will be the drug of choice over chemo. Safer and more effective. The market may have it swings but if you buy and hold, you won't be sorry. Never this low again. Just had to pass on.
Agree. PCYC already announced plans to submit one indication at the end of this year. With today's milestone payment, I just don't get why they sold more shares two months ago. They're hiring like crazy, including a commercial team, but the cash seems more than sufficient. And I would rather they tap into Janssen more for the commercial launch and build that out much later.
Don't underestimate Mr. Duggan - a brilliant tactician.
During the last CC Mr. Duggan said that sales and marketing will not be a gate. He is front loading manufacturing, sales and marketing so when approval occurs, all that will be left is to print the label. Demand is self evident.
Autoimmune - I would not expect a partnership - but I get ahead of myself. CC as ASCO will be revealing.